Press Releases

Back to previous page

Regen Biologics CMIâ„¢ Topic of Symposium

FRANKLIN LAKES, NJ -- May 31, 2006 --   More than 60 surgeons from across Europe participated in a seminar discussing the latest data and updates on ReGen’s CMI.  Professor Maurilio Marcacci, MD, PhD, of Bologna, Italy chaired the seminar. The faculty included J.R. Steadman, MD and W. G. Rodkey, DVM of Vail, Colorado, D. Holsten, MD of Koblenz, Germany and P. Bulgheroni, MD of Varese, Italy.

The seminar was held during the 12th ESSKA meeting in Innsbruck, Austria last week.  ESSKA is the European Society of Sports Traumatology, Knee Surgery and Arthroscopy.

Four presentations were made during the symposium, including an update on the long-term follow-up of an early CMI feasibility study, a discussion of tissue gain noted in the U.S. Multicenter Clinical Trial, an illustration of a new all-inside suture technique being used during some CMI procedures, and a review of morphological evolution and MRI findings subsequent to CMI implantation.

Commenting on the event, Gerald E. Bisbee, Jr., Ph.D., Chairman and Chief Executive Officer of ReGen Biologics said, “We were pleased with the enthusiastic participation at this event.  As use of the CMI becomes even more widespread, and as more surgeons gain experience and knowledge, we look forward to similar venues for surgeon interaction and training.”

The ESSKA meeting also provided an occasion for investigators to gather and discuss the ongoing post-marketing surveillance for the lateral CMI, which was approved for use in Europe earlier this year.  Surgeons reviewed the surgical technique, patient selection criteria, and initial results observed in the patients treated to date.

About ReGen Biologics, Inc.
ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's patented collagen scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery.  The Company’s first approved product using its collagen scaffold technology is the CMI™, a meniscus application of its collagen scaffold technology, which is cleared for sale in Europe and marketed through the Company’s European subsidiary ReGen Biologics AG.

ReGen is headquartered in Franklin Lakes, NJ and manufactures its collagen scaffold products in its ISO Certified facility located in Redwood City, CA.  For more information on ReGen, visit www.regenbio.com.

This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of the management of ReGen and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's 2005 annual report on Form 10-K and additional filings with the SEC. ReGen's filings with the SEC are available to the public at the Company's website at http://www.regenbio.com, from commercial document-retrieval services, and at the Web site maintained by the SEC at http://www.sec.gov.

About the European Society of Sports Traumatology, Knee Surgery and Arthroscopy
Please visit www.esska.org.

Contacts:

ReGen Europe:
Thomas B. Fischer
ReGen Biologics AG
Appenzell, Switzerland
+41 (0) 79 500 79 54
thomas.fischer@regenbio.com

ReGen USA:
Brion Umidi
Chief Financial Officer
ReGen Biologics, Inc.
(201) 651-3515
bumidi@regenbio.com

Investor Relations:
Al Palombo
Cameron Associates
Investor Relations
(212) 245-8800 Ext. 209
al@cameronassoc.com